Scandion Oncology

Overcoming cancer drug resistance

Navbar
  • Research & Development
    • Pipeline
    • Clinical Development
    • Science
      • Cancer drug resistance
      • Technology Platform
      • SCO-101
  • News & Press
    • Press releases
  • Investors
    • Share information
    • Financial calendar
    • Financial Reports
      • Annual reports
      • Interim reports
    • Presentations
    • Business development
    • Analyst Coverage
    • Prospectuses
      • Subscription warrants
      • Rights Issue 2024
      • Rights Issue 2022
      • Rights Issue 2020
      • Rights Issue 2019
      • Subscription Warrant (SCOL TO 1)
      • IPO 2018
    • Corporate governance
    • General meetings
Skip to content

Press releases

  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
16 December 2020Regulatory Scandion Oncology A/S – Flagging message Download Presentation Webcast Workbook
15 December 2020Regulatory Scandion Oncology: Supplement to previously published press release regarding the outcome of Scandion Oncology’s rights issue Download Presentation Webcast Workbook
15 December 2020Regulatory SCANDION ONCOLOGY ANNOUNCES OUTCOME IN THE RIGHTS ISSUE Download Presentation Webcast Workbook
24 November 2020Regulatory Scandion Oncology publishes prospectus relating to the rights issue and announces the intention of changing listing venue to Nasdaq First North Growth Market Sweden Download Presentation Webcast Workbook
17 November 2020Regulatory Correction of previously published press release regarding Scandion Oncology’s rights issue (trading in BTAs) Download Presentation Webcast Workbook
16 November 2020Regulatory The Board of Directors of Scandion Oncology has resolved on a fully guaranteed rights issue of approximately SEK 236 million Download Presentation Webcast Workbook
13 November 2020 Correction: Scandion Oncology – Minutes of extraordinary general meeting Download Presentation Webcast Workbook
13 November 2020Regulatory Scandion Oncology – Minutes of extraordinary general meeting Download Presentation Webcast Workbook
28 October 2020Regulatory Scandion Oncology: Notice to convene Extraordinary General Meeting in Scandion Oncology A/S Download Presentation Webcast Workbook
28 October 2020Regulatory Scandion Oncology A/S initiates its second clinical study with SCO-101 Download Presentation Webcast Workbook
9 October 2020Regulatory Scandion Oncology announces that the warrant exercise is registered at the Danish Companies Registration Office Download Presentation Webcast Workbook
7 October 2020Regulatory Scandion Oncology announces modified timelines for clinical studies Download Presentation Webcast Workbook
  1. Frontpage
  2. Press releases
  3. Press release

About us

Research & Development

  • Research & Development
  • Pipeline
  • Clinical Development
  • Science

News & Press

  • Press releases
  • Other news
  • Image library items
  • Video library items

Investors

  • Investors
  • Share information
  • Financial Reports
  • Presentations
  • Analyst Coverage
  • Prospectuses
  • Corporate governance
  • Events

Scandion Oncology - The Cancer Drug Resistance Company

Our vision is to overcome cancer drug resistance in order to improve lives for cancer patients and their families

© Copyright 2022 - Scandion Oncology A/S | We use cookies to improve our services | Disclaimer: Market data could be delayed. Delivered by Cision.